Michael Barbella, Managing Editor04.08.21
Intersect ENT Inc. has welcomed Neil Hattangadi, M.D., M.Sc. to its Board of Directors. Hattangadi will serve as a member of the Nominating and Corporate Governance Committee of the Board.
“We are thrilled to have Neil join the Intersect ENT Board. He brings a wealth of experience in building successful companies as well as highly relevant ENT expertise,” said Thomas A. West, president and CEO of Intersect ENT. “Neil is a clinician, innovator and business leader with an exceptional track record. His experience and inquisitive and collaborative demeanor make him an excellent fit for our Board.”
Hattangadi is co-founder and CEO of Cortica Inc., a high-growth technology-enabled autism service provider. Previously, he served as president and chief operating officer of ENT startup Spirox Inc., where he launched the Latera implant for Nasal Airway Obstruction. Spirox was sold to Entellus Medical, another ENT company. Earlier in his career Hattangadi ran the global Peripheral Vascular business at Royal Phillips and Volcano Corporation. Hattangadi currently serves as a board member of the venous stent company Vesper Medical.
Hattangadi earned a B.S.E. from Duke University, M.Sc. as a Rhodes Scholar from Oxford University, and an M.D. from Harvard Medical School.
“I’m excited to have the opportunity to contribute to Intersect ENT,” said Hattangadi. “I look forward to helping make localized drug delivery with the PROPEL and SINUVA implants the standard of care in rhinosinusitis while also helping the management team expand Intersect ENT’s product and technology portfolio across the continuum of ENT care.”
“We are thrilled to have Neil join the Intersect ENT Board. He brings a wealth of experience in building successful companies as well as highly relevant ENT expertise,” said Thomas A. West, president and CEO of Intersect ENT. “Neil is a clinician, innovator and business leader with an exceptional track record. His experience and inquisitive and collaborative demeanor make him an excellent fit for our Board.”
Hattangadi is co-founder and CEO of Cortica Inc., a high-growth technology-enabled autism service provider. Previously, he served as president and chief operating officer of ENT startup Spirox Inc., where he launched the Latera implant for Nasal Airway Obstruction. Spirox was sold to Entellus Medical, another ENT company. Earlier in his career Hattangadi ran the global Peripheral Vascular business at Royal Phillips and Volcano Corporation. Hattangadi currently serves as a board member of the venous stent company Vesper Medical.
Hattangadi earned a B.S.E. from Duke University, M.Sc. as a Rhodes Scholar from Oxford University, and an M.D. from Harvard Medical School.
“I’m excited to have the opportunity to contribute to Intersect ENT,” said Hattangadi. “I look forward to helping make localized drug delivery with the PROPEL and SINUVA implants the standard of care in rhinosinusitis while also helping the management team expand Intersect ENT’s product and technology portfolio across the continuum of ENT care.”